The At its meeting in December 2022 a Recommendation for approval for Tremelimumab (Imjudo, AstraZeneca):
The monoclonal antibody should be used in combination with durvalumab as first-line treatment for adults with advanced or unresectable hepatocellular carcinoma.
This full text is unfortunately reserved for medical professionals
You have reached the maximum number of articles for unregistered visitors
Source — https://www.univadis.de/viewarticle/ema-empfiehlt-zulassung-f%25C3%25BCr-tremelimumab-2022a10028o7
Comments are closed.